PDF(1143 KB)
PDF(1143 KB)
PDF(1143 KB)
儿童朗格罕斯细胞组织细胞增生症34例临床分析
Clinical features and prognosis of Langerhans cell histiocytosis in children: an analysis of 34 cases
目的 探讨儿童朗格罕斯细胞组织细胞增生症（LCH）的临床特点和预后，以期提高LCH诊疗水平。方法 对34例初发LCH儿童患者进行回顾性分析。结果 34例患者中位年龄14.5个月（22 d至60个月），其中0~2岁的23例、> 2岁的11例；高危组17例，低危组17例。30例患者接受化疗，6周化疗总有效率67%（20/30），12个月总有效率87%（26/30），3年总生存（OS）率为86%±6%，3年无事件生存（EFS）率为64%±9%。高危组患者6周化疗有效率46.7%，3年OS为72%±12%，3年EFS为46%±13%，均低于低危组（86.7%、100%、82%±9%），差异均有统计学意义（P < 0.05）。高危组12个月化疗有效率（80%）与低危组（93%）的差异无统计学意义（P > 0.05）；复发率和死亡率均为27%，而低危组无复发和死亡。结论 LCH总体生存率较高，但高危组6周化疗有效率低，远期预后较差。
Objective To investigate the clinical features and prognosis of children with Langerhans cell histiocytosis (LCH). Methods A retrospective analysis was performed for the clinical data of 34 children with newly diagnosed LCH. Results The 34 children had a median age of 14.5 months (range:22 d to 60 months). Of all 34 children, 23 were aged 0-2 years and 11 were aged > 2 years. There were 17 children in the high-risk group and 17 in the low-risk group. Thirty children received chemotherapy, and the 6-week and 12-month overall response rates were 67% (20/30) and 87% (26/30), respectively. The 3-year overall survival (OS) rate was 86%±6% and the 3-year event-free survival (EFS) rate was 64%±9%. Compared with the low-risk group, the high-risk group had significantly lower 6-week chemotherapy response rate (47% vs 87%; P < 0.05), 3-year OS rate (72%±12% vs 100%; P < 0.05), and 3-year EFS rate (46%±13% vs 82%±9%; P < 0.05). There was no significant difference in the 12-month chemotherapy response rate between the high-risk and low-risk groups (80% vs 93; P > 0.05). The high-risk group had a recurrence rate of 27% and a mortality rate of 27%. There were no recurrence or deaths in the low-risk group. Conclusions Children with LCH have a high overall survival rate, but the high-risk patient has a low 6-week response rate of induction chemotherapy and poor long-term prognosis.
朗格罕斯细胞组织细胞增生症 / 治疗 / 预后 / 儿童
Langerhans cell histiocytosis / Treatment / Prognosis / Child
[1] Allen CE, Li L, Peters TL, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells[J]. J Immunol, 2010, 184(8):4557-4667.
[2] Minkov M. Multisystem Langerhans cell histiocytosis in children:current treatment and future directions[J]. Paediatr Drugs, 2011, 13(2):75-86.
[3] Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients:a pilot study from the Histiocyte Society-Late Effects Study Group[J]. Pediatr Blood Cancer, 2004, 42(5):438-444.
[4] 高举, 袁粒星. 朗格汉斯细胞组织细胞增生症的诊断和治疗[J]. 实用儿科临床杂志, 2006, 21(15):1037-1040.
[5] 吴升华. 朗格汉斯细胞组织细胞增生症评估与治疗指南介绍[J]. 中华儿科杂志, 2012, 50(2):155-158.
[6] Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis[J]. J Pediatr, 2001, 138(5):728-734.
[7] Grois N, Pötschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis[J]. Pediatr Blood Cancer, 2006, 46(2):228-233.
[8] Fahrner B, Prosch H, Minkov M, et al. Long-term outcome of hypothalamic pituitary tumors in Langerhans cell histiocytosis[J]. Pediatr Blood Cancer, 2012, 58(4):606-610.
[9] Ronceray L, Pötschger U, Janka G, et al. Pulmonary involvement in pediatric-onset multisystem Langerhans cell histiocytosis:effect on course and outcome[J]. J Pediatr, 2012, 161(1):129-133.
[10] Gadner H, Heitger A, Grois N, et al. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group[J]. Med Pediatr Oncol, 1994, 23(2):72-80.
[11] Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis[J]. Blood, 2013, 121(25):5006-5014.
[12] Farran RP, Zaretski E, Egeler RM. Treatment of Langerhans cell histiocytosis with pamidronate[J]. J Pediatr Hematol Oncol, 2001, 23(1):54-56.
[13] Weitzman S, Braier J, Donadieu J, et al. 2'-Chlorodeoxyadeno-
sine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH) results of the LCH-S-98 protocol of the Histiocyte Society[J]. Pediatr Blood Cancer, 2009, 53(7):1271-1276.
[14] Gadner H, Grois N, Pötschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification[J]. Blood, 2008, 111(5):2556-2562.
[15] 吴方方,高怡瑾,潘慈,等.儿童多脏器受累朗格汉斯细胞组织细胞增生症131例临床研究[J].中华儿科杂志, 2016, 54(5):349-353.
[16] 宋爱琴, 李学荣, 庞秀英, 等. 儿童朗格汉斯细胞组织细胞增生症26例临床分析[J]. 临床儿科杂志, 2011, 29(5):431-434.
[17] 黄俊彬,江莉,陈纯,等.改良DAL-HX83/90和JLSG-96方案治疗儿童朗格汉斯细胞组织细胞增生症的疗效比较[J].中国实验血液学杂志, 2016, 24(4):1190-1195.
[18] Bernard F, Thomas C, Bearand Y, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction[J]. Eur J Cancer, 2005, 41(17):2682-2689.
[19] Héritier S, Emile JF, Barkaoui MA, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy[J]. J Clin Oncol, 2016, 34(25):3023-3030.
[20] Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma[J]. N Engl J Med, 2014, 371(20):1867-1876.
[21] Long GV, Stroyakovskiy D, Gogas H, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma:a multicentre. double-blind, phase 3 randomised controlled trial[J]. Lancet, 2015, 386(9992):444-451.
[22] 泥永安, 孙立荣. 朗格汉斯细胞组织细胞增生症治疗进展[J].临床儿科杂志, 2015, 33(3):291-293.
